drugset / Trial / NCT00950950

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

NCT00950950

Phase 1 Completed 24 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of romosozumab in postmenopausal women with low bone mass.

Timeline

Start
2009-08-18
Primary completion
2010-08-19
Completion
2010-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Romosozumab Monoclonal antibody 3 mg/kg Subcutaneous

Indications